View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 4, 2021updated 31 Jan 2022 6:57pm

CTI BioPharma’s pacritinib fails to meet primary goal in Covid study

Pacritinib was found to be well-tolerated in the PRE-VENT trial with reduced number of grade 3+ events.

CTI BioPharma has reported topline data where its oral drug, pacritinib, failed to meet statistical significance for the primary goal of the PRE-VENT clinical trial in severe Covid-19 patients admitted to hospital.

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

Pacritinib is an experimental oral kinase inhibitor.

The double-blind, randomised, placebo-controlled multicentre trial analysed pacritinib plus standard of care against placebo plus standard of care in Covid-19 subjects and included those with and without cancer.

The proportion of subjects advancing to receive invasive mechanical ventilation and/or extracorporeal membrane oxygenation or succumbed by day 28 was the trial’s primary goal.

The trial was recently modified to a Phase II design due to the accessibility to Covid-19 vaccines and the evolving pandemic situation.

The final assessment was carried out after randomising 200 subjects in the trial.

According to the trial findings, 26.3% of subjects in the pacritinib arm progressed to receive invasive mechanical ventilation and/or extracorporeal membrane oxygenation or died by day 28 Versus 24.8% in the placebo arm.

Data suggest that the treatment did not offer a statistically significant improvement in the primary goal, CTI BioPharma noted.

Pacritinib was demonstrated to be well-tolerated in subjects with reduced rates of grade 3+ events.

Serious adverse events were observed in the pacritinib arm versus the placebo arm.

CTI BioPharma president and CEO Adam Craig said: “Last year, we launched the PRE-VENT study of pacritinib in patients with severe Covid-19 in response to the pandemic and an unprecedented medical need to improve outcomes for these patients.

“Although pacritinib was well tolerated on study, it did not demonstrate a clinical benefit in treating the sickest patients with Covid-19.”

Based on the latest trial data, the company decided not to progress the pacritinib development to treat patients with severe Covid-19.

Related Companies

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena